Barnes C. Importance of pharmacokinetics in the management of hemophilia. Pediatr Blood Cancer 2013;60:S27-9. DOI: https://doi.org/10.1002/pbc.24339

[Fondo colombiano de enfermedades de alto costo. Situaciòn de la hemofilia en Colombia, 2018.] Available from: https://www.cuentadealtocosto.org/site/images/Publicaciones/Situacion_Hemofilia_2018.pdf.

Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs. J Intern Med 1994;236:391-9. DOI: https://doi.org/10.1111/j.1365-2796.1994.tb00815.x

Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:1935-9. DOI: https://doi.org/10.1111/jth.12672

Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment guidelines working group on behalf of The World Federation Of Hemophilia. Haemophilia 2013;19:e1-47. DOI: https://doi.org/10.1111/j.1365-2516.2012.02909.x

Fischer K, Poonnoose P, Dunn A, et al. Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia 2017;23:11-24. DOI: https://doi.org/10.1111/hae.13088

Nilsson IM, Berntorp E, Lofquist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32. DOI: https://doi.org/10.1111/j.1365-2796.1992.tb00546.x

Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophlia A and B. Acta Orthop Scand Suppl 1965;77:3-132. DOI: https://doi.org/10.3109/ort.1965.36.suppl-77.01

Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia 2014;20:607-15. DOI: https://doi.org/10.1111/hae.12438

Blanchette V, O´Mahony B, McJames L, Mahlangu J. Assessment of outcomes. Haemophilia 2014;20:114-20. DOI: https://doi.org/10.1111/hae.12426

Fischer K, Berntorp E. Targeting factor replacement therapy in severe hemophilia: which level is important?. Semin Thromb Hemost 2015;41:860-63. DOI: https://doi.org/10.1055/s-0035-1552562

Berntorp E. If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. J Thromb Haemost 2017;15:1103-05. DOI: https://doi.org/10.1111/jth.13682

[FMH (Federación Mundial de Hemofilia). ¿Qué es la profilaxis?, 2014.] Available from: http://www1.wfh.org/publications/files/pdf-1587.pdf.

Fernandes S, Carvalho M, Lopes M, Araujo F. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. Semin Thromb Hemost 2014;40:785-89. DOI: https://doi.org/10.1055/s-0034-1394109

Collins PW. Personalized prophylaxis. Haemophilia 2012;18,131–35. DOI: https://doi.org/10.1111/j.1365-2516.2012.02838.x

McEneny-King A, Lorio A, Foster G, Edginton AN. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opinion on Drug Metabolism & Toxicology 2016;12:1313-21. DOI: https://doi.org/10.1080/17425255.2016.1214711

Carcao M, Lorio A. Individualizing factor replacement therapy in severe hemophilia. Semin Thromb Hemost 2015;41:864-871. DOI: https://doi.org/10.1055/s-0035-1552563

[Federación Mundial de Hemofilia (FMH). Guías para el tratamiento de la hemofilia, 2012.] Available from: http://www1.wfh.org/publications/files/pdf-1513.pdf.

Lorio A, Keepanasseril A, Foster G, et al. Development of a web-accessible population pharmacokinetic service – Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc 2016; 5:e.239. DOI: https://doi.org/10.2196/resprot.6558

Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001;40:815-32. DOI: https://doi.org/10.2165/00003088-200140110-00003

Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012;38:79-94. DOI: https://doi.org/10.1055/s-0031-1300954

Sun HL, McIntosh KA, Squire SJ, et al. Patient powered prophylaxis: a 12‐month study of individualized prophylaxis in adults with severe haemophilia A. Haemophilia 2017;23:877‐883. DOI: https://doi.org/10.1111/hae.13319

Pasca S, Milan M, Sarolo L, Zanon E. PK‐driven prophylaxis versus standard prophylaxis: when a tailored treatment may be a real and achievable cost‐saving approach in children with severe hemophilia A. Thromb Res 2017;157:58-63. DOI: https://doi.org/10.1016/j.thromres.2017.07.003

Lissitchkov T, Rusen L, Georgiev P, et al. PK-guided personalized prophylaxis with Nuwiq (human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia 2017;23:697-704. DOI: https://doi.org/10.1111/hae.13251

Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993;51:247-252. DOI: https://doi.org/10.1111/j.1600-0609.1993.tb00638.x